A Systematic Review on the Association of Acquired Human Cytomegalovirus Infection with Hearing Loss

A Systematic Review on the Association of Acquired Human Cytomegalovirus Infection with Hearing Loss

Default Cytomegalovirus infection (CMV) induces clinical syndrome which is usually associated with hearing loss. However, the effect of CVM infection obtained in adults and children has not been clearly defined. The purpose of this review is to critically assess the scientific evidence of the Association of CMV infection obtained by postnatal or tinnitus hearing loss. Systematic Overview of Records Reporting Sensorineural Loss (SNHL) or Tinnitus and CMV infection obtained including articles published in English is done.

The search strategy is limited to human studies with CMV infection obtained. After screening and quality assessment, nine studies involving 1528 individuals meet inclusion criteria. A total of 14% of patients with SNHL showed evidence of previous exposure to CMV, while in individuals without SNHL (control) percentage rose to 19.3%. SNHL was reported as unilateral or bilateral at 15.3%, and was not determined in 84.7% of cases. SNHL levels range from mild to deep for children and adults. None of the records reported by Tinitus.

The prevalence of children or adults with SNHL acquired by CMV infection obtained confirmed by polymerase chain reaction (PCR) or low IgM anti-CMV antibodies. Fenotyping of patients with CMV infection obtained is limited to hearing loss with pure tone audiometry and no additional audiological tests carried out in most studies. Additional symptoms deserve more attention, including vertigo episodic or tinnitus, because some patients with the clinical spectrum of meniere disease can result from a latent infection of CMV.

Nitrate oxide flows metabolic regulations mediated by a virus during human cytomegalovirus infection

Nitric Oxide is a multipurpose and critical effector molecule that can modulate many cellular functions. Although it is recognized as a regulator of infection, the inhibition mechanism of nitric oxide on human cytomegalovirus replication (HCMV) is still difficult to understand. We show that nitric oxide weakens viral replication by disrupting modulation mediated by HCMV from several cellular processes.

Nitric oxide exposure reduces the synthesis of HCMV genomes and offspring virus infections with differences depending on the type of cell. Mitochondrial respiration greatly reduced both in infected and infected cells HCMV during exposure with a slight impact at the ATP level which shows changes in cellular metabolism. Metabolomics identifies small molecules that change significantly in several routes during exposure to nitrate oxide including nucleotide biosynthesis, tricarboxylic acid cycles (TCA), and glutamine metabolism. Glutathione metabolites increased to coincide with the reduction of glutamine precursor glutathione.

This shift is accompanied by an increase in antioxidant enzymes. Glutamine deprivation imitated defects in HCMV replication and mitochondrial respiration observed during exposure to nitrate oxide. This data shows that nitric oxide limits glutamineolysis by diverting glutamine to glutathione synthesis. In addition, lipid intermediaries are challenuous, which is likely to contribute to the increase in virus particles observed. Nitric Oxide interferes with several cellular processes, and we have limited success in saving defects replication by adding metabolic intermediaries. Our studies show that the ace of nitrate oxide from HCMV is multifactorial with interference with cellular metabolic viruses that play a central role. The importance of human cytomegalovirus is a common pathogen in patients with a compromised immune system, including transplant patients and during innate infections. Lytic HCMV replication is likely to occur on local infection sites with immune cells that infiltrate and release nitrate oxide with other effector molecules.

A Systematic Review on the Association of Acquired Human Cytomegalovirus Infection with Hearing Loss

The clinical results of the recipients of alogenic hematopoietic stem cell transplants develop DNAEMIA CYTOMEGALOVIRUS before the endraftment

There is limited information about the impact of DNAEMIA CMV episodes that develop before the endraftment (pre-cmv dnaemia) in clinical results after alogenic hematopoietic stem cell transplantation (allo-HSCT). This problem is intended for retrospective multicenter studies currently including 878 patients. All participating centers use the preemptive antivirus therapy strategy for prevention of CMV disease. The load of CMV DNA in the blood is monitored by a real-time PCR test. A total of 144 patients (cumulative events were 16.5%, 95% CI, 14% -19%) had a pre-CMV dnaemia episode on the median 10 days after allo-HSCT.

Patients who develop pre-CMV Dnaemia have a significant probability of recurrent episodes (P = <0.001) (50%) than those who experience post-CMV dnaemia (32.9%); However, the incidence of comparable CMV disease (p = 0.52). The cumulative incidence of the overall death (OM) and non-relapse mortality (NRM) at 1 year after the Allo-HSCT was 32% (95% CI, 29-35%) and 23% (95% CI 20-26%), respectively -Masing. The risk of OM and NRM in a customized model emerged proportion to patients who developed a DNAemia CMV episode, regardless of whether it happened before or after the endraftment, in patients with CMV CMV episodes before and post-engraftment or on those without CMV Dnaemia.

Cytomegalovirus Retinitis After transplantation of alogenic hematopoietic stem cells under the active screening of cytomegalovirus antigenemia

Although Cytomegalovirus (CMV) remains a major cause of morbidity and mortality after transplantation of hematopoietic stem cells (HSCT), the incidence of CMV retinitis is considered lower than the incidence of CMV infection in other organs after the shite. In this study, the incidence and characteristics of CMV retinitis were retrospectively evaluated at the Alogenic HSCT receiver. Eye playback is carried out on the development of ocular symptoms or positive CMV infections using peripheral blood evaluated by antigenemia PP65 or a polymerase chain reaction. Of the 514 patients, 13 patients developed CMV retinitis. The median onset of CMV retinitis is day 34 (range, 21-118) post transplants, and cumulative events are 2.5% (95% CI, 1.6-42) at 6 months after transplantation.

NUMBL Conjugated Antibody

C38379 100ul
EUR 476.4

anti- NUMBL antibody

FNab05917 100µg
EUR 606.3
Description: Antibody raised against NUMBL

anti- NUMBL antibody

FNab05918 100µg
EUR 702
Description: Antibody raised against NUMBL

Anti-NUMBL antibody

PAab05917 100 ug
EUR 426

Anti-NUMBL antibody

STJ24849 100 µl
EUR 332.4

Anti-NUMBL antibody

STJ70424 100 µg
EUR 430.8

Anti-NUMBL antibody

STJ116023 100 µl
EUR 332.4

NUMBL Polyclonal Antibody

A70355-020 20 ul
EUR 117.7

NUMBL Polyclonal Antibody

A70355-050 50 ul
EUR 293.7

NUMBL Polyclonal Antibody

A70355-100 100 ul
EUR 470.8

NUMBL Polyclonal Antibody

A70355
  • EUR 754.26
  • EUR 117.70
  • EUR 293.70
  • EUR 470.80
  • 100 ?g
  • 20 ul
  • 50 ul
  • 100 ul

NUMBL siRNA

20-abx926610
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

NUMBL siRNA

20-abx926611
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

NUMBL Peptide

43-109P 0.1 mg
EUR 405.6

NUMBL siRNA

20-abx903703
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

NUMBL Antibody, HRP conjugated

1-CSB-PA897595LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against NUMBL. Recognizes NUMBL from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

NUMBL Antibody, FITC conjugated

1-CSB-PA897595LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against NUMBL. Recognizes NUMBL from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

NUMBL Antibody, Biotin conjugated

1-CSB-PA897595LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against NUMBL. Recognizes NUMBL from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

NUMBL cloning plasmid

CSB-CL897595HU-10ug 10ug
EUR 704.4
Description: A cloning plasmid for the NUMBL gene.

NUMBL Blocking Peptide

DF6863-BP 1mg
EUR 234

NUMBL Rabbit pAb

A14088-100ul 100 ul
EUR 369.6

NUMBL Rabbit pAb

A14088-200ul 200 ul
EUR 550.8

NUMBL Rabbit pAb

A14088-20ul 20 ul
EUR 219.6

NUMBL Rabbit pAb

A14088-50ul 50 ul
EUR 267.6

NUMBL Rabbit pAb

A2140-100ul 100 ul
EUR 369.6

NUMBL Rabbit pAb

A2140-200ul 200 ul
EUR 550.8

NUMBL Rabbit pAb

A2140-20ul 20 ul
EUR 219.6

NUMBL Rabbit pAb

A2140-50ul 50 ul
EUR 267.6

Polyclonal NUMBL Antibody (N-Term)

AMM06872G 0.1 mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human NUMBL (N-Term). This antibody is tested and proven to work in the following applications:

NUMBL Polyclonal Antibody, HRP Conjugated

A70356-050 50 ul
EUR 293.7

NUMBL Polyclonal Antibody, HRP Conjugated

A70356-100 100 ul
EUR 470.8

NUMBL Polyclonal Antibody, FITC Conjugated

A70357-050 50 ul
EUR 293.7

NUMBL Polyclonal Antibody, FITC Conjugated

A70357-100 100 ul
EUR 470.8

NUMBL Polyclonal Antibody, Biotin Conjugated

A70358-050 50 ul
EUR 293.7

NUMBL Polyclonal Antibody, Biotin Conjugated

A70358-100 100 ul
EUR 470.8

NUMBL Polyclonal Antibody, HRP Conjugated

A70356
  • EUR 754.26
  • EUR 293.70
  • EUR 470.80
  • 100 ?g
  • 50 ul
  • 100 ul

NUMBL Polyclonal Antibody, FITC Conjugated

A70357
  • EUR 754.26
  • EUR 293.70
  • EUR 470.80
  • 100 ?g
  • 50 ul
  • 100 ul

NUMBL Polyclonal Antibody, Biotin Conjugated

A70358
  • EUR 754.26
  • EUR 293.70
  • EUR 470.80
  • 100 ?g
  • 50 ul
  • 100 ul

Human NUMBL shRNA Plasmid

20-abx956126
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Mouse NUMBL shRNA Plasmid

20-abx971842
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Rat NUMBL shRNA Plasmid

20-abx988573
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

NUMBL ELISA KIT|Human

EF001382 96 Tests
EUR 826.8

NUMBL Recombinant Protein (Human)

RP021901 100 ug Ask for price

NUMBL Recombinant Protein (Rat)

RP214829 100 ug Ask for price

NUMBL Recombinant Protein (Mouse)

RP155453 100 ug Ask for price

Polyclonal NUMBLIKE / NUMBL Antibody (N-Terminus)

AMM06873G 0.05ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NUMBLIKE / NUMBL (N-Terminus). This antibody is tested and proven to work in the following applications:

Numbl ORF Vector (Rat) (pORF)

ORF071611 1.0 ug DNA
EUR 607.2

NUMBL ORF Vector (Human) (pORF)

ORF007301 1.0 ug DNA
EUR 114

Numbl ORF Vector (Mouse) (pORF)

ORF051819 1.0 ug DNA
EUR 607.2

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

abx117223-100ug 100 ug
EUR 560.4

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

20-abx001752
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

20-abx334204
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

abx431475-200ul 200 ul
EUR 460.8

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

abx235917-100ug 100 ug
EUR 577.2

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody

abx235918-100ug 100 ug
EUR 661.2

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody (HRP)

20-abx336868
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody (FITC)

20-abx336869
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

NUMB Like, Endocytic Adaptor Protein (NUMBL) Antibody (Biotin)

20-abx336870
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Numbl sgRNA CRISPR Lentivector set (Rat)

K7619801 3 x 1.0 ug
EUR 406.8

NUMBL sgRNA CRISPR Lentivector set (Human)

K1467301 3 x 1.0 ug
EUR 406.8

Numbl sgRNA CRISPR Lentivector set (Mouse)

K4473701 3 x 1.0 ug
EUR 406.8

Numbl sgRNA CRISPR Lentivector (Rat) (Target 1)

K7619802 1.0 ug DNA
EUR 184.8

Numbl sgRNA CRISPR Lentivector (Rat) (Target 2)

K7619803 1.0 ug DNA
EUR 184.8

Numbl sgRNA CRISPR Lentivector (Rat) (Target 3)

K7619804 1.0 ug DNA
EUR 184.8

Human Numb- like protein, NUMBL ELISA KIT

ELI-44511h 96 Tests
EUR 988.8

Mouse Numb- like protein, Numbl ELISA KIT

ELI-35534m 96 Tests
EUR 1038

NUMBL sgRNA CRISPR Lentivector (Human) (Target 1)

K1467302 1.0 ug DNA
EUR 184.8

NUMBL sgRNA CRISPR Lentivector (Human) (Target 2)

K1467303 1.0 ug DNA
EUR 184.8

NUMBL sgRNA CRISPR Lentivector (Human) (Target 3)

K1467304 1.0 ug DNA
EUR 184.8

Numbl sgRNA CRISPR Lentivector (Mouse) (Target 1)

K4473702 1.0 ug DNA
EUR 184.8

Numbl sgRNA CRISPR Lentivector (Mouse) (Target 2)

K4473703 1.0 ug DNA
EUR 184.8

Numbl sgRNA CRISPR Lentivector (Mouse) (Target 3)

K4473704 1.0 ug DNA
EUR 184.8

NUMBL Protein Vector (Human) (pPB-C-His)

PV029201 500 ng Ask for price

NUMBL Protein Vector (Human) (pPB-N-His)

PV029202 500 ng Ask for price

NUMBL Protein Vector (Human) (pPM-C-HA)

PV029203 500 ng Ask for price

NUMBL Protein Vector (Human) (pPM-C-His)

PV029204 500 ng Ask for price

NUMBL Protein Vector (Mouse) (pPB-C-His)

PV207274 500 ng
EUR 723.6

NUMBL Protein Vector (Mouse) (pPB-N-His)

PV207275 500 ng
EUR 723.6

NUMBL Protein Vector (Mouse) (pPM-C-HA)

PV207276 500 ng
EUR 723.6

NUMBL Protein Vector (Mouse) (pPM-C-His)

PV207277 500 ng
EUR 723.6

NUMBL Protein Vector (Rat) (pPB-C-His)

PV286442 500 ng
EUR 723.6

NUMBL Protein Vector (Rat) (pPB-N-His)

PV286443 500 ng
EUR 723.6

NUMBL Protein Vector (Rat) (pPM-C-HA)

PV286444 500 ng
EUR 723.6

NUMBL Protein Vector (Rat) (pPM-C-His)

PV286445 500 ng
EUR 723.6

Numbl 3'UTR Luciferase Stable Cell Line

TU214290 1.0 ml Ask for price

Numbl 3'UTR GFP Stable Cell Line

TU264290 1.0 ml Ask for price

Numbl 3'UTR Luciferase Stable Cell Line

TU114428 1.0 ml Ask for price

Numbl 3'UTR GFP Stable Cell Line

TU164428 1.0 ml Ask for price

NUMBL 3'UTR GFP Stable Cell Line

TU066094 1.0 ml
EUR 1825.2

NUMBL 3'UTR Luciferase Stable Cell Line

TU016094 1.0 ml
EUR 1825.2

NUMBL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV661351 1.0 ug DNA
EUR 818.4

NUMBL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV661355 1.0 ug DNA
EUR 818.4

NUMBL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV661356 1.0 ug DNA
EUR 818.4

Human NUMB Like, Endocytic Adaptor Protein (NUMBL) ELISA Kit

abx381926-96tests 96 tests
EUR 1093.2

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7619805 3 x 1.0 ug
EUR 451.2

NUMBL sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K1467305 3 x 1.0 ug
EUR 451.2

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K4473705 3 x 1.0 ug
EUR 451.2

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7619806 1.0 ug DNA
EUR 200.4

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7619807 1.0 ug DNA
EUR 200.4

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7619808 1.0 ug DNA
EUR 200.4

NUMBL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K1467306 1.0 ug DNA
EUR 200.4

NUMBL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K1467307 1.0 ug DNA
EUR 200.4

NUMBL sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K1467308 1.0 ug DNA
EUR 200.4

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K4473706 1.0 ug DNA
EUR 200.4

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K4473707 1.0 ug DNA
EUR 200.4

Numbl sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K4473708 1.0 ug DNA
EUR 200.4

NUMBL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV661352 1.0 ug DNA
EUR 818.4

NUMBL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV661353 1.0 ug DNA
EUR 888

NUMBL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV661354 1.0 ug DNA
EUR 888

ASAP1 antibody Antibody

DF8746 200ul
EUR 420

CD11b Antibody Antibody

ABD2911 100 ug
EUR 525.6

anti- Antibody^Polyclonal antibody control antibody

LSMab09882 100 ug
EUR 525.6

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.08ML 0.08 ml
EUR 165

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.4ML 0.4 ml
EUR 379

Antibody

A1360-500 Ask for price

Ly1 Antibody Reactive (LYAR) Antibody

20-abx123734
  • EUR 493.20
  • EUR 710.40
  • 100 ul
  • 200 ul

Anti-Glycolipid Antibody (AGA) Antibody

20-abx004855
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Ly1 Antibody Reactive (LYAR) Antibody

20-abx014333
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Ly1 Antibody Reactive (LYAR) Antibody

20-abx008109
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-400ul 400 ul
EUR 627.6

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-80l 80 µl
EUR 343.2

Anti-Glycolipid Antibody (AGA) Antibody

abx036399-100ug 100 ug
EUR 469.2

Anti-Glycolipid Antibody (AGA) Antibody

abx230204-100ug 100 ug
EUR 577.2

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319900
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319901
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319905
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319913
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

20-abx311665
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

20-abx324434
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

abx234901-100ug 100 ug
EUR 661.2

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 332.4
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 332.4

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 332.4

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 332.4

Five patients present ocular symptoms on onset. In eight asymptomatic patients remaining, the diagnosis of CMV retinitis is made by screening guided by a positive CMV infection. All patients can be evaluated responding to antivirus treatment but three shows an increase incomplete with the sequel to ocular. Our results show that the incidence of CMV retinitis after the Alogenic HSCT cannot be ignored and active ophthalmological screening is not only based on symptoms but also monitoring positive CMV infection contributes to early diagnosis of CMV retinitis.

Leave A Comment